US Chronic Urticaria Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.33 BnPlaceholder estimate
Estimate 2025$1.41 Bn34.5% of the global market
Projected 2034$2.32 Bn 64.7%Adds $910.3 Mn over 9 forecast years
CAGR 2025–20345.7%Faster than 47% of 180 Pharmaceuticals markets here
Key players5
US is 34.47% of the global market.
In North America, the largest is US (this report) at $1.41 Bn.
21 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Chronic Urticaria Treatment Market Analysis Executive Summary
Chronic urticaria treatments control long-lasting hives and itching that do not go away with standard antihistamines.
Key segments of the chronic Urticaria Treatment market include drug class (Antihistamines, Anti-IgE Biologics and BTK Inhibitors) and type (Chronic Spontaneous Urticaria and Chronic Inducible Urticaria).
US Chronic Urticaria Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Chronic Urticaria Treatment Market Dynamics
Market Growth Drivers
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the chronic Urticaria Treatment market. Biosimilars are widening access.
Opportunity
New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the chronic Urticaria Treatment market room to grow.
Market Restraints
High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the chronic Urticaria Treatment market.
Competitive Landscape for Chronic Urticaria Treatment Market in US
The chronic Urticaria Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Chronic Urticaria Treatment Market in US
Chronic Urticaria Treatment in the US: rules, payment and research
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 21 studies on Chronic Urticaria Treatment that are recruiting, active or about to start in the US.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for chronic Urticaria Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Type
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novartis
7.2 Sanofi
7.3 Regeneron Pharmaceuticals
7.4 Celldex Therapeutics
7.5 Roche
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The chronic Urticaria Treatment market can be segmented based on various criteria, including drug class, type and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Chronic Urticaria Treatment right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Chronic Urticaria Treatment in context
The US compared
Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the Chronic Urticaria Treatment market in the US?
Placeholder estimate: about $1.41 Bn in 2025, rising to about $2.32 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Chronic Urticaria Treatment market in the US growing?
Placeholder estimate: about 5.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Chronic Urticaria Treatment market report cover?
The report splits the market by drug class (Antihistamines, Anti-IgE Biologics, BTK Inhibitors, Others), type (Chronic Spontaneous Urticaria, Chronic Inducible Urticaria) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Chronic Urticaria Treatment market?
Key players include Novartis AG, Sanofi, Regeneron Pharmaceuticals, Celldex Therapeutics and Roche.
What is driving the Chronic Urticaria Treatment market?
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the chronic Urticaria Treatment market. Biosimilars are widening access.
Who regulates Chronic Urticaria Treatment in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Chronic Urticaria Treatment are running in the US?
21 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Chronic Urticaria Treatment?
PubMed lists 677 papers on Chronic Urticaria Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US 
Canada
China
Japan
Germany
Brazil
France
UK
Italy
India
Spain
Ecuador
Saudi Arabia
Mexico
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Thailand
Singapore
Kenya